Oxaliplatin-induced thrombotic thrombocytopenic purpura: Case report and literature review

Journal of Clinical Oncology

Volumn 30, Issue 31, 2012, Pages

  Niu, Jiaxin ^a   Mims, Martha P ^b  

^a CANCER TREATMENT CENTERS OF AMERICA   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ASPARTATE AMINOTRANSFERASE; BEVACIZUMAB; BILIRUBIN; CREATININE; FLUOROURACIL; FOLINIC ACID; GLYCERYL TRINITRATE; HAPTOGLOBIN; IRINOTECAN; LACTATE DEHYDROGENASE; OXALIPLATIN; PREDNISONE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CASE REPORT; COOMBS TEST; CRYOTHERAPY; DISEASE SEVERITY; DRUG MEGADOSE; EMERGENCY CARE; ERYTHROCYTE; FEMALE; HUMAN; HYPERTENSION; ILEOSTOMY; JAUNDICE; LIVER METASTASIS; LUNG METASTASIS; MEDICAL HISTORY; MEDICAL LITERATURE; PARTIAL HEPATECTOMY; PARTIAL THROMBOPLASTIN TIME; PLASMAPHERESIS; PRIORITY JOURNAL; RECTUM CARCINOMA; THORAX PAIN; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADENOCARCINOMA; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; ORGANOPLATINUM COMPOUNDS; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RECTAL NEOPLASMS;

EID: 84869142030     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.42.5082     Document Type: Article

References (23)

1. Moake J: Thrombotic thrombocytopenia purpura (TTP) and other thrombotic microangiopathies. Best Pract Res Clin Haematol 22:567-576, 2009
2. Dlott JS, Danielson CF, Blue-Hnidy DE, et al: Drug-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: A concise review. Ther Apher Dial 8:102-111, 2004 (Pubitemid 38796940)
3. Lesesne JB, Rothschild N, Erickson B, et al: Cancer-associated hemolyticuremic syndrome: Analysis of 85 cases from a national registry. J Clin Oncol 7:781-789, 1989 (Pubitemid 19145601)
4. Pirrotta MT, Bucalossi A: Thrombotic microangiopathy and occult neoplasia. Cardiovasc Hematol Disord Drug Targets 10:87-93, 2010
5. El-Ghazal R, Podoltsev N, Marks P, et al: Mitomycin-C-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: Cumulative toxicity of an old drug in a new era. Clin Colorectal Cancer 10:142-145, 2011
6. Humphreys BD, Sharman JP, Henderson JM, et al: Gemcitabine-associated thrombotic microangiopathy. Cancer 100:2664-2670, 2004 (Pubitemid 38715773)
7. Furlan M, Lämmle B: Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: The role of von Willebrand factor-cleaving protease. Best Pract Res Clin Haematol 14:437-454, 2001 (Pubitemid 32677088)
8. McCarthy LJ, Dlott JS, Orazi A, et al: Thrombotic thrombocytopenic purpura: Yesterday, today, tomorrow. Ther Apher Dial 8:80-86, 2004 (Pubitemid 38796936)
9. Furlan M: Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome. Adv Nephrol Necker Hosp 30:71-81, 2000
10. Caramazza D, Quintini G, Abbene I, et al: Relapsing or refractory idiopathic thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: The role of rituximab. Transfusion 50:2753-2760, 2010
11. Pisoni R, Ruggenenti P, Remuzzi G: Drug-induced thrombotic microangiopathy: Incidence, prevention and management. Drug Saf 24:491-501, 2001 (Pubitemid 32595762)
12. Nazzal M, Safi F, Arma F, et al: Micafungin-induced thrombotic thrombocytopenic purpura: A case report and review of the literature. Am J Ther 18:e258-e260, 2011
13. Zakarija A, Bennett C: Drug-induced thrombotic microangiopathy. Semin Thromb Hemost 31:681-690, 2005 (Pubitemid 43063086)
14. Valavaara R, Nordman E: Renal complications of mitomycin C therapy with special reference to the total dose. Cancer 55:47-50, 1985 (Pubitemid 15198197)
15. Sun W, Haller DG: Adjuvant therapy for colon cancer. Curr Oncol Rep 7:181-185, 2005 (Pubitemid 40674344)
16. Van Loon K, Venook AP: Adjuvant treatment of colon cancer: What is next? Curr Opin Oncol 23:403-409, 2011
17. Raftery L, Goldberg RM: Optimal delivery of cytotoxic chemotherapy for colon cancer. Cancer J 16:214-219, 2010
18. Allegra CJ, Yothers G, O'Connell MJ, et al: Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol 27:3385-3390, 2009
19. Buti S, Riccò M, Chiesa MD, et al: Oxaliplatin-induced hemolytic anemia during adjuvant treatment of a patient with colon cancer: A case report. Anticancer Drugs 18:297-300, 2007 (Pubitemid 46192983)
20. Curtis BR, Kaliszewski J, Marques MB, et al: Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin. Am J Hematol 81:193-198, 2006
21. Pavic M, Moncharmont P, Sève P, et al: Oxaliplatin-induced immune thrombocytopenia. Gastroenterol Clin Biol 30:797-798, 2006
22. Saif MW, The A, Ledbetter L: Oxaliplatin-mediated autoimmune thrombocytopenia. Clin Colorectal Cancer 8:61-62, 2009
23. Zupancic M, Shah PC, Shah-Khan F: Gemcitabine-associated thrombotic thrombocytopenic purpura. Lancet Oncol 8:634-641, 2007 (Pubitemid 46995635)